KEY TAKEAWAY: A study in JAMA found  “a Markov cohort state-transition model determined that adding evolocumab at current list price to patients receiving standard background therapy was estimated to cost $268 637 per quality-adjusted life-year gained. Sensitivity and scenario analyses demonstrated incremental cost-effectiveness ratios ranging from $100 193 to $488 642 per quality-adjusted life-year.” Will this be enough to sway insurers to say “ok”?

healthinsuranceEmployees are contributing nearly 6% more for health insurance for their families in 2013, more than three times the increase in workers’ wages.  Workers are shelling out an average of $4,565 for their employer-sponsored family health coverage this year, according to the annual survey conducted by the Kaiser Family Foundation and the Health Research & Educational Trust.  What does this mean for DTC marketers and patient behavior ?